Skip to content

Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric.

Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric: Study of Superiority, Randomized, Controlled, Prospective, Single Blind

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03393299
Acronym
REVOR
Enrollment
65
Registered
2018-01-08
Start date
2018-01-16
Completion date
2018-10-30
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Use, Quality of Life

Keywords

elderly people, geriatric short-stay, STOPP/START criteria

Brief summary

Assess the impact of the systematic use of STOPP/START tool during medication conciliation on the evolution of hospitalised elderly people's quality of life at 2 months.

Interventions

software which helps to do the drug reconciliation

Sponsors

Lille Catholic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with more than 75 years old * Hospitalized in geriatrics short-stay * Patient with a written informed consent * Patient with a social security scheme

Exclusion criteria

* Severe dementia * Not able to respond to SF-12 * Disease at final stage * Patient under legal protection (maintenance of justice, tutelage, legal guardianship)

Design outcomes

Primary

MeasureTime frameDescription
SF-12 Quality of life scaleat inclusion and at 2 monthsThe evolution of the hospitalised elderly people's quality of life at 2 months will be measured by the SF-12 scale.

Secondary

MeasureTime frameDescription
Proportion of patients rehospitalizedat 2 monthsThe proportion of patients that have been rehospitalized (unscheduled hospitalization) during the two months following inclusion will be measured.
Number of fallsat 2 monthsThe number of falls during the two months following the inclusion will be collected for each patient.
Mortalityat 2 monthsThe mortality during the two months following inclusion will be measured.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026